NURIX THERAPEUTICS INC. - COMMON STOCK

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

09 Feb 2023 16:15:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

08 Feb 2023 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

09 Jan 2023 08:35:39 By Nasdaq GlobeNewswire

Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 07:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

15 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

12 Dec 2022 17:30:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting

07 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in

10 Nov 2022 09:00:02 By Nasdaq GlobeNewswire

Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies

10 Nov 2022 09:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

03 Nov 2022 09:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

02 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit

26 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit

19 Oct 2022 09:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update

06 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

05 Oct 2022 08:00:02 By Nasdaq GlobeNewswire

Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors

14 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

31 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces $40 Million Registered Direct Offering

08 Jul 2022 08:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces $55 Million Registered Direct Offering

07 Jul 2022 17:03:06 By Nasdaq GlobeNewswire